TABLE 3.
Costs and health outcomes for HSCT patients
| Treatment | Total cost (SGD) | Effectivenessa |
ICER |
||||
|---|---|---|---|---|---|---|---|
| No. of IFIs | No. of IFIs avoided | LY | LY saved | Per IFI avoided | Per LY saved | ||
| Fluconazole | 4,271.27 | 0.100 | 6.247 | ||||
| Itraconazole capsule | 5,893.90 | 0.135 | −0.035 | 6.172 | −0.075 | Dominated | Dominated |
| Itraconazole solution | 4,697.85 | 0.066 | 0.034 | 6.320 | 0.073 | 12,546 | 5,844 |
| Posaconazole | 5,960.76 | 0.037 | 0.063 | 6.383 | 0.136 | 26,817 | 12,423 |
| Voriconazole | 17,442.68 | 0.049 | 0.051 | 6.357 | 0.110 | 258,263 | 119,740 |
a
IFI, invasive fungal infection; LY, life-years; ICER, incremental cost-effectiveness ratio.